SETD2 and immunodeficiency disease: We used published or newly established array-based methylomes [Illumina Human Methylation 450K (HM450K) or EPIC BeadChip arrays; see Material and Methods] from patients with pathogenic variations in DNMT3A in Tatton-Brown Rahman (TBRS) [33], DNMT3B in Immunodeficiency Centromeric instability and Facial anomalies (ICF1) [34], NSD1/KMT3A in Sotos [35], SETD2 in Sotos-like [36] [also known as Luscan Lumish [37], and KMT2D/MLL2 in Kabuki [38] syndromes.